Content-Adaptive Variable Framerate Encoding Scheme for Green Live Streaming

Adaptive live video streaming applications use a fixed predefined configuration for the bitrate ladder with constant framerate and encoding presets in a session. However, selecting optimized framerates and presets for every bitrate ladder representation can enhance perceptual quality, improve computational resource allocation, and thus, the streaming energy efficiency. In particular, low framerates for low-bitrate representations reduce compression artifacts and decrease encoding energy consumption. In addition, an optimized preset may lead to improved compression efficiency. To this light, this paper proposes a Content-adaptive Variable Framerate (CVFR) encoding scheme, which offers two modes of operation: ecological (ECO) and high-quality (HQ). CVFR-ECO optimizes for the highest encoding energy savings by predicting the optimized framerate for each representation in the bitrate ladder. CVFR-HQ takes it further by predicting each representation's optimized framerate-encoding preset pair using low-complexity discrete cosine transform energy-based spatial and temporal features for compression efficiency and sustainable storage. We demonstrate the advantage of CVFR using the x264 open-source video encoder. The results show that CVFR-ECO yields an average PSNR and VMAF increase of 0.02 dB and 2.50 points, respectively, for the same bitrate, compared to the fastest preset highest framerate encoding. CVFR-ECO also yields an average encoding and storage energy consumption reduction of 34.54% and 76.24%, considering a just noticeable difference (JND) of six VMAF points. In comparison, CVFR-HQ yields an average increase in PSNR and VMAF of 2.43 dB and 10.14 points, respectively, for the same bitrate. Finally, CVFR-HQ resulted in an average reduction in storage energy consumption of 83.18%, considering a JND of six VMAF points

Robust estimation of bacterial cell count from optical density

Optical density (OD) is widely used to estimate the density of cells in liquid culture, but cannot be compared between instruments without a standardized calibration protocol and is challenging to relate to actual cell count. We address this with an interlaboratory study comparing three simple, low-cost, and highly accessible OD calibration protocols across 244 laboratories, applied to eight strains of constitutive GFP-expressing E. coli. Based on our results, we recommend calibrating OD to estimated cell count using serial dilution of silica microspheres, which produces highly precise calibration (95.5% of residuals <1.2-fold), is easily assessed for quality control, also assesses instrument effective linear range, and can be combined with fluorescence calibration to obtain units of Molecules of Equivalent Fluorescein (MEFL) per cell, allowing direct comparison and data fusion with flow cytometry measurements: in our study, fluorescence per cell measurements showed only a 1.07-fold mean difference between plate reader and flow cytometry data

Elevating Your Streaming Experience with Just Noticeable Difference (JND)-based Encoding

International audienc

Just noticeable difference-aware per-scene bitrate-laddering for adaptive video streaming

In video streaming applications, a fixed set of bitrate-resolution pairs (known as a bitrate ladder) is typically used during the entire streaming session. However, an optimized bitrate ladder per scene may result in (i) decreased storage or delivery costs or/and (ii) increased Quality of Experience. This paper introduces a Just Noticeable Difference (JND)-aware perscene bitrate ladder prediction scheme (JASLA) for adaptive video-on-demand streaming applications. JASLA predicts jointly optimized resolutions and corresponding constant rate factors (CRFs) using spatial and temporal complexity features for a given set of target bitrates for every scene, which yields an efficient constrained Variable Bitrate encoding. Moreover, bitrate-resolution pairs that yield distortion lower than one JND are eliminated. Experimental results show that, on average, JASLA yields bitrate savings of 34.42% and 42.67% to maintain the same PSNR and VMAF, respectively, compared to the reference HTTP Live Streaming (HLS) bitrate ladder Constant Bitrate encoding using x265 HEVC encoder, where the maximum resolution of streaming is Full HD (1080p). Moreover, a 54.34% average cumulative decrease in storage space is observed

All-intra rate control using low complexity video features for Versatile Video Coding

Versatile Video Coding (VVC) allows for large compression efficiency gains over its predecessor, High Efficiency Video Coding (HEVC). The added efficiency comes at the cost of increased runtime complexity, especially for encoding. It is thus highly relevant to explore all available runtime reduction options. This paper proposes a novel first pass for two-pass rate control in all-intra configuration, using low-complexity video analysis and a Random Forest (RF)-based machine learning model to derive the data required for driving the second pass. The proposed method is validated using VVenC, an open and optimized VVC encoder. Compared to the default two-pass rate control algorithm in VVenC, the proposed method achieves around 32% reduction in encoding time for the preset faster, while on average only causing 2% BD-rate increase and achieving similar rate control accuracy.Comment: Accepted in IEEE International Conference on Image Processing (ICIP), 202

Long-term (180-Day) outcomes in critically Ill patients with COVID-19 in the REMAP-CAP randomized clinical trial

Importance The longer-term effects of therapies for the treatment of critically ill patients with COVID-19 are unknown. Objective To determine the effect of multiple interventions for critically ill adults with COVID-19 on longer-term outcomes. Design, Setting, and Participants Prespecified secondary analysis of an ongoing adaptive platform trial (REMAP-CAP) testing interventions within multiple therapeutic domains in which 4869 critically ill adult patients with COVID-19 were enrolled between March 9, 2020, and June 22, 2021, from 197 sites in 14 countries. The final 180-day follow-up was completed on March 2, 2022. Interventions Patients were randomized to receive 1 or more interventions within 6 treatment domains: immune modulators (n = 2274), convalescent plasma (n = 2011), antiplatelet therapy (n = 1557), anticoagulation (n = 1033), antivirals (n = 726), and corticosteroids (n = 401). Main Outcomes and Measures The main outcome was survival through day 180, analyzed using a bayesian piecewise exponential model. A hazard ratio (HR) less than 1 represented improved survival (superiority), while an HR greater than 1 represented worsened survival (harm); futility was represented by a relative improvement less than 20% in outcome, shown by an HR greater than 0.83. Results Among 4869 randomized patients (mean age, 59.3 years; 1537 [32.1%] women), 4107 (84.3%) had known vital status and 2590 (63.1%) were alive at day 180. IL-6 receptor antagonists had a greater than 99.9% probability of improving 6-month survival (adjusted HR, 0.74 [95% credible interval {CrI}, 0.61-0.90]) and antiplatelet agents had a 95% probability of improving 6-month survival (adjusted HR, 0.85 [95% CrI, 0.71-1.03]) compared with the control, while the probability of trial-defined statistical futility (HR >0.83) was high for therapeutic anticoagulation (99.9%; HR, 1.13 [95% CrI, 0.93-1.42]), convalescent plasma (99.2%; HR, 0.99 [95% CrI, 0.86-1.14]), and lopinavir-ritonavir (96.6%; HR, 1.06 [95% CrI, 0.82-1.38]) and the probabilities of harm from hydroxychloroquine (96.9%; HR, 1.51 [95% CrI, 0.98-2.29]) and the combination of lopinavir-ritonavir and hydroxychloroquine (96.8%; HR, 1.61 [95% CrI, 0.97-2.67]) were high. The corticosteroid domain was stopped early prior to reaching a predefined statistical trigger; there was a 57.1% to 61.6% probability of improving 6-month survival across varying hydrocortisone dosing strategies. Conclusions and Relevance Among critically ill patients with COVID-19 randomized to receive 1 or more therapeutic interventions, treatment with an IL-6 receptor antagonist had a greater than 99.9% probability of improved 180-day mortality compared with patients randomized to the control, and treatment with an antiplatelet had a 95.0% probability of improved 180-day mortality compared with patients randomized to the control. Overall, when considered with previously reported short-term results, the findings indicate that initial in-hospital treatment effects were consistent for most therapies through 6 months